RHYTHM PHARMACEUTICALS, INC. Payments to Acquire Short-term Investments
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Payments to Acquire Short-term Investments of $85.69 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-08-04
- RHYTHM PHARMACEUTICALS, INC. payments to acquire short-term investments for the quarter ending 2026-06-30 was $43.49M, a 61.33% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. payments to acquire short-term investments for the quarter ending 2026-03-31 was $42.20M, a 25.89% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. payments to acquire short-term investments for the quarter ending 2025-12-31 was $20.35M, a 69.35% decline year-over-year.
- RHYTHM PHARMACEUTICALS, INC. payments to acquire short-term investments for the quarter ending 2025-09-30 was $267.85M, a 97.49% increase year-over-year.
- RHYTHM PHARMACEUTICALS, INC. payments to acquire short-term investments for fiscal 2025 was $348.67M, a 29.95% increase from fiscal 2024.
- RHYTHM PHARMACEUTICALS, INC. payments to acquire short-term investments for fiscal 2024 was $268.31M, a 24.40% decline from fiscal 2023.
- RHYTHM PHARMACEUTICALS, INC. payments to acquire short-term investments for fiscal 2023 was $354.92M, a 40.88% increase from fiscal 2022.
- RHYTHM PHARMACEUTICALS, INC. payments to acquire short-term investments for fiscal 2022 was $251.94M, a 52.01% decline from fiscal 2021.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $43.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $85.69M 10-Q · filed 2026-08-04 | $106.03M derived: sum of 3 quarters · filed 2026-08-04 | $373.88M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $42.20M 10-Q · filed 2026-05-05 | $62.55M derived: sum of 2 quarters · filed 2026-05-05 | $330.39M derived: sum of 3 quarters · filed 2026-05-05 | $357.35M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $20.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $288.19M derived: sum of 2 quarters · filed 2026-02-26 | $315.15M derived: sum of 3 quarters · filed 2026-08-04 | $348.67M 10-K · filed 2026-02-26 |
| 2025-09-30 | $267.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $294.80M derived: sum of 2 quarters · filed 2026-08-04 | $328.32M 10-Q · filed 2025-11-04 | $394.70M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $26.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $60.48M 10-Q · filed 2026-08-04 | $126.85M derived: sum of 3 quarters · filed 2026-08-04 | $262.48M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $33.52M 10-Q · filed 2026-05-05 | $99.90M derived: sum of 2 quarters · filed 2026-05-05 | $235.52M derived: sum of 3 quarters · filed 2026-05-05 | |
| 2024-12-31 | $66.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $202.00M derived: sum of 2 quarters · filed 2026-02-26 | $268.31M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $135.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $201.94M 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | $66.31M 10-Q · filed 2025-08-05 | |||
| 2023-12-31 | $40.65M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $209.84M derived: sum of 2 quarters · filed 2026-02-26 | $285.27M derived: sum of 3 quarters · filed 2026-02-26 | $354.92M 10-K · filed 2026-02-26 |
| 2023-09-30 | $169.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $244.62M derived: sum of 2 quarters · filed 2024-11-06 | $314.26M 10-Q · filed 2024-11-06 | $414.68M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | $75.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $145.08M 10-Q · filed 2024-08-06 | $245.49M derived: sum of 3 quarters · filed 2025-02-28 | $346.57M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $69.64M 10-Q · filed 2024-05-07 | $170.06M derived: sum of 2 quarters · filed 2025-02-28 | $271.14M derived: sum of 3 quarters · filed 2025-02-28 | $282.10M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $100.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $201.50M derived: sum of 2 quarters · filed 2025-02-28 | $212.46M derived: sum of 3 quarters · filed 2025-02-28 | $251.94M 10-K · filed 2025-02-28 |
| 2022-09-30 | $101.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $112.04M derived: sum of 2 quarters · filed 2023-11-08 | $151.52M 10-Q · filed 2023-11-08 | $220.25M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $10.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | $50.44M 10-Q · filed 2023-08-01 | $119.17M derived: sum of 3 quarters · filed 2024-02-29 | $212.94M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $39.48M 10-Q · filed 2023-05-02 | $108.21M derived: sum of 2 quarters · filed 2024-02-29 | $201.98M derived: sum of 3 quarters · filed 2024-02-29 | $266.91M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $68.73M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $162.50M derived: sum of 2 quarters · filed 2024-02-29 | $227.43M derived: sum of 3 quarters · filed 2024-02-29 | $524.97M 10-K · filed 2024-02-29 |
| 2021-09-30 | $93.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $158.70M derived: sum of 2 quarters · filed 2022-11-08 | $456.24M 10-Q · filed 2022-11-08 | $489.71M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-06-30 | $64.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $362.47M 10-Q · filed 2022-08-03 | $395.94M derived: sum of 3 quarters · filed 2023-03-01 | $405.93M derived: sum of 4 quarters · filed 2023-03-01 |
| 2021-03-31 | $297.54M 10-Q · filed 2022-05-03 | $331.01M derived: sum of 2 quarters · filed 2023-03-01 | $341.00M derived: sum of 3 quarters · filed 2023-03-01 | $369.04M derived: sum of 4 quarters · filed 2023-03-01 |
| 2020-12-31 | $33.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $43.46M derived: sum of 2 quarters · filed 2023-03-01 | $71.50M derived: sum of 3 quarters · filed 2023-03-01 | $86.87M 10-K · filed 2023-03-01 |
| 2020-09-30 | $9.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $38.03M derived: sum of 2 quarters · filed 2021-11-02 | $53.40M 10-Q · filed 2021-11-02 | $238.28M derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $28.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $43.41M 10-Q · filed 2021-08-03 | $228.29M derived: sum of 3 quarters · filed 2021-08-03 | $269.36M derived: sum of 4 quarters · filed 2021-08-03 |
| 2020-03-31 | $15.37M 10-Q · filed 2021-05-03 | $200.25M derived: sum of 2 quarters · filed 2021-05-03 | $241.32M derived: sum of 3 quarters · filed 2021-05-03 | $255.38M derived: sum of 4 quarters · filed 2021-05-03 |
| 2019-12-31 | $184.88M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $225.95M derived: sum of 2 quarters · filed 2021-03-01 | $240.01M derived: sum of 3 quarters · filed 2021-03-01 | $295.82M 10-K · filed 2021-03-01 |
| 2019-09-30 | $41.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-02 | $55.13M derived: sum of 2 quarters · filed 2020-11-02 | $110.95M 10-Q · filed 2020-11-02 | $170.98M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $14.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-03 | $69.88M 10-Q · filed 2020-08-03 | $129.91M derived: sum of 3 quarters · filed 2021-03-01 | $298.06M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $55.82M 10-Q · filed 2020-05-04 | $115.85M derived: sum of 2 quarters · filed 2021-03-01 | $284.00M derived: sum of 3 quarters · filed 2021-03-01 | $302.39M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $60.03M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $228.18M derived: sum of 2 quarters · filed 2021-03-01 | $246.57M derived: sum of 3 quarters · filed 2021-03-01 | $248.59M 10-K · filed 2021-03-01 |
| 2018-09-30 | $168.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-01 | $186.54M derived: sum of 2 quarters · filed 2019-11-01 | $188.56M 10-Q · filed 2019-11-01 | $302.45M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $18.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-29 | $20.41M 10-Q · filed 2019-07-29 | $134.31M derived: sum of 3 quarters · filed 2020-03-02 | $134.31M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $2.02M 10-Q · filed 2019-05-03 | $115.92M derived: sum of 2 quarters · filed 2020-03-02 | $115.92M derived: sum of 3 quarters · filed 2020-03-02 | $116.93M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $113.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $113.90M derived: sum of 2 quarters · filed 2020-03-02 | $114.91M derived: sum of 3 quarters · filed 2020-03-02 | $126.92M 10-K · filed 2020-03-02 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $1.01M derived: sum of 2 quarters · filed 2018-11-09 | $13.02M 10-Q · filed 2018-11-09 | $17.03M derived: sum of 4 quarters · filed 2019-03-08 |
| 2017-06-30 | $1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-08 | $13.02M 10-Q · filed 2018-08-08 | $17.03M derived: sum of 3 quarters · filed 2019-03-08 | |
| 2017-03-31 | $12.01M 10-Q · filed 2018-05-14 | $16.02M derived: sum of 2 quarters · filed 2019-03-08 | ||
| 2016-12-31 | $4.01M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-08 | $15.22M 10-K · filed 2019-03-08 | ||
| 2016-09-30 | $11.21M 10-Q · filed 2017-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |